Magnesium and Vitamin D Combination for Post-COVID Syndrome
Post-COVID-19 Syndrome, Long COVID, Vitamin D Deficiency
About this trial
This is an interventional treatment trial for Post-COVID-19 Syndrome focused on measuring Post-COVID syndrome, Long COVID, Vitamin D, Magnesium
Eligibility Criteria
Inclusion Criteria: Men and women aged 18 or older. Previous diagnosis of COVID-19, confirmed by Real Time Polymerase Chain Reaction (RT-PCR) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Diagnosis of post-COVID syndrome Hypomagnesemia Vitamin D deficiency Exclusion Criteria: Subjects who have received magnesium and/or vitamin D supplements in the last 30 days
Sites / Locations
- Biomedical Research Unit. IMSS. Durango
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Intervention group
Control group.
Will receive 1.2 g of magnesium chloride (equivalent to 360 mg of magnesium elemental) + 4000 IU of vitamin D once a day, for four months.
Will receive inert placebo for four months.